MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by United Therapeutics Corporation (United Therapeutics) with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil Injection is ...

Liquidia Technologies, Inc. (LQDA) shares rallied 14.1% in the last trading session to close at $10.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 33% loss over the past four weeks.The sudden rise in the stock price was observed after Liquidia announced the pricing of an underwritten public offering and a concurrent private placement which is expected to raise gross proceeds of approximately $67.5 millio ...

MORRISVILLE, N.C., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (the “Company” or “Liquidia”), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the pricing of an underwritten public offering and a concurrent private placement, with anticipated total gross proceeds of approximately $67.5 million, before deducting underwriting discounts and commissions, and expenses. The Company offered 6,460,674 shares of co ...

MORRISVILLE, N.C., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the following investor conferences this September: 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, from 11:00 – 11:35 a.m. ET2024 Cantor Global Healthcare Conference in New York on Thursday, September 19, 2024, from 1:30 – 1:50 p.m. ...

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA) on behalf of Liquidia stockholders. Our investigation concerns whether Liquidia has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 19, 2024, Liquidia issued a press release announcing ...

NEW YORK, Aug. 26, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Liquidia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action] On August 19, 2024, ...

MORRISVILLE, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it has filed litigation in the U.S. District Court of the District of Columbia (Case No. 1:24-cv-02428) that challenges the recent decision by the United States Food and Drug Administration (FDA) to grant 3-year new clinical investigation exclusivity (NCI exclusivity) to Tyvaso DPI®. FDA gran ...

Shares of Liquidia Corporation (LQDA) lost nearly 31% on Monday after the FDA delayed granting full approval to its Yutrepia (treprostinil) inhalation powder in a pair of lung disorder indications.The FDA granted tentative approval to Yutrepia for a second indication — in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug was initially granted tentative approval for use in adults with pulmonary arterial hypertension (PAH) in 2021.A tentative approval indicates th ...

BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Liquidia Corp. (Nasdaq: LQDA) for potential securities law violations. Investors who have lost money in their Liquidia Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/lqda. What is this all about? Liquidia shares have dropped 35% today following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug ...

U.S. stock futures were slightly higher this morning, with the S&P 500 futures gaining around 0.1% on Monday.Shares of Liquidia Corporation LQDA fell sharply in today's pre-market trading.The company announced that the FDA granted tentative approval of YUTREPIA inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.Liquidia shares dipped 36.3% to $8.98 in pre-market trading.Here are some big stocks recording losses in today ...